The Octopus Value Investing
Authors
The Octopus Value Investing

The Octopus Value Investing

Public companies research, value investig philosophy and much more.

PandoraPandora

+1+1

Pandora A/S - Q3 2025 Earnings Review

The Market Turns Overly Pessimistic on External Headwinds Not Only Affecting Pandora

The Octopus Value Investing

The Octopus Value Investing

Earnings ReviewEarnings Review

+1+1

Novo Nordisk - Q3 2025 Earnings Review

Disappointing, Yes. Unexpected, No.

The Octopus Value Investing

The Octopus Value Investing

MiscellaneousMiscellaneous

#4 Investment Sidebar Snapshots

September 2025 News & Insights Recap

The Octopus Value Investing

The Octopus Value Investing

Theon InternationalTheon International

Theon International - Quantitative Analysis

Financials just made my conviction grow bigger

The Octopus Value Investing

The Octopus Value Investing

MiscellaneousMiscellaneous

#3 Investment Sidebar Snapshots

Monlunabant, Novo Nordisk & Lesson from 10 Years of US Biosimilars Market

The Octopus Value Investing

The Octopus Value Investing

PandoraPandora

+1+1

Pandora A/S - H1 2025 Earnings Review

The Stocks Plunging While the Company is Meeting the FY25 Guidance

The Octopus Value Investing

The Octopus Value Investing

Novo NordiskNovo Nordisk

Novo Nordisk - H1 2025 Earnings Review

Lars Fruergaard's Final Earnings as CEO

The Octopus Value Investing

The Octopus Value Investing

PandoraPandora

Alexander Lacik, CEO of Pandora, Interview in "Ett Rikare Liv" Podcast

Highlights and Transcripts Translated to English

The Octopus Value Investing

The Octopus Value Investing

The Octopus PortfolioThe Octopus Portfolio

#4 The Journey of Compounding - H1 2025 Letter to Readers

Reflections of a Hectic Semester in the Market

The Octopus Value Investing

The Octopus Value Investing

MiscellaneousMiscellaneous

+1+1

#2 Investment Sidebar Snapshots

Compiling One Month of Novo Nordisk News & Updates

The Octopus Value Investing

The Octopus Value Investing